R J A van Moorselaar
Overview
Explore the profile of R J A van Moorselaar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
479
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beijert I, van den Burgt Y, Hentschel A, Bosschieter J, Kauer P, Lissenberg-Witte B, et al.
World J Urol
. 2024 Oct;
42(1):578.
PMID: 39412544
Purpose: Although cystoscopy is a reliable tool for detecting bladder cancer, it poses a high burden on patients and entails high costs. This highlights the need for non-invasive and cost-effective...
2.
van Riel L, Kets C, van Hest L, Menko F, Boerrigter B, Franken S, et al.
Fam Cancer
. 2024 Jun;
23(4):579-582.
PMID: 38900222
No abstract available.
3.
van Riel L, van de Beek I, Wolthuis R, Boerrigter B, van Moorselaar R, Houweling A
Ned Tijdschr Geneeskd
. 2023 Jun;
167.
PMID: 37345626
Background: Several hereditary disorders, with highly variable and sometimes difficult to recognize manifestations, can present with a spontaneous pneumothorax. Options to perform DNA-testing have changed rapidly, as a result of...
4.
Yildirim H, Schuurman M, Widdershoven C, Lagerveld B, van den Brink L, Ruiter A, et al.
BJUI Compass
. 2023 Jun;
4(4):455-463.
PMID: 37334025
Objectives: To analyse variation in clinical management of cT1 renal cell carcinoma (RCC) in the Netherlands related to surgical hospital volume (HV). Materials And Methods: Patients diagnosed with cT1 RCC...
5.
Bodar Y, Luining W, Keizer B, Meijer D, Vellekoop A, Schaaf M, et al.
Urol Oncol
. 2023 Jan;
41(4):205.e17-205.e24.
PMID: 36588019
Purpose: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is an emerging staging tool for patients with primary high-risk prostate cancer (PCa). Patients with primary metastatic disease are staged...
6.
Vernooij R, Cremers R, Jansen H, Somford D, Kiemeney L, van Andel G, et al.
Urol Oncol
. 2022 Jun;
40(7):353.
PMID: 35654644
No abstract available.
7.
Janssen J, Staal F, Brouwer C, Langendijk J, de Jong I, van Moorselaar R, et al.
BMC Cancer
. 2022 May;
22(1):482.
PMID: 35501744
Background: More than 60% of oligo-recurrent prostate cancer (PCa) patients treated with metastasis-directed radiotherapy (MDRT) develop biochemical recurrence within 2 years. This recurrence rate emphasises the need for improved treatment...
8.
Hagens M, Veerman H, de Ligt K, Tillier C, van Leeuwen P, van Moorselaar R, et al.
J Robot Surg
. 2021 Jun;
16(2):453-462.
PMID: 34120255
The objective is to evaluate the effect of robot-assisted radical prostatectomy (RARP)-related postoperative complications on the 6-month postoperative health-related quality of life (HRQoL). A total of 1008 patients underwent a...
9.
Westgeest H, Kuppen M, van den Eertwegh A, de Wit R, Bergman A, van Moorselaar R, et al.
Prostate Cancer Prostatic Dis
. 2021 Mar;
24(3):871-879.
PMID: 33746212
Background: In 2004 docetaxel was the first life-prolonging drug (LPD) registered for metastatic castration-resistant prostate cancer (mCRPC) patients. Between 2011 and 2014 new LPDs for mCRPC (cabazitaxel, abiraterone, enzalutamide, and...
10.
Bodar Y, Jansen B, van der Voorn J, Zwezerijnen G, Meijer D, Nieuwenhuijzen J, et al.
World J Urol
. 2020 Oct;
39(7):2439-2446.
PMID: 33079250
Purpose: In primary prostate cancer (PCa) patients, accurate staging and histologic grading are crucial to guide treatment decisions. F-DCFPyL (PSMA)-PET/CT has been successfully introduced for (re)staging PCa, showing high accuracy...